TBH, one thing you have not clearly articulated is that since IPO, the company has drawn in circa $20Million in revenue. The difference now is they are debt free and cash flow positive.
It was a train wreck as they failed the FDA approval for febridx numerous times and were not producing much else since IPO.
The price likely to remain around .038mark until CR is complete.
Further revenue from Febridx will move this up and only because the company has been fixated on its release. They dont provide much clarity around the services they provide even though they sell themselves as a serivces company first.
LDX Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
